A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
about
Epigenetic treatment of solid tumours: a review of clinical trialsThe histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibitionDesigns for phase I trials in ordered groups.A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial.A combination of p300 and Braf expression in the diagnosis and prognosis of melanomaSuberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell lineSelective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewHDAC inhibitors in kidney development and disease.Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma.Potential biofluid markers and treatment targets for renal cell carcinoma.Management of metastatic kidney cancer in the era of personalized medicine.Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.Targeted polytherapy in small cell sarcoma and its association with doxorubicin.Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications.Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.
P2860
Q26773803-6F158C5A-7EA3-4D7B-9B3D-E72785AF68C2Q28542639-27983E7F-F99B-443C-86E8-49336FC30E7CQ30275947-B7E4BB24-9808-441F-9AD6-8D3C349575C2Q30299964-0F7EE985-93A4-4A36-A412-15FAEF9A604FQ33733125-556DD5E1-F651-463D-B35D-5DE3F9D4E45BQ35232590-4D20E9D3-8400-4714-801B-75438DA57C0DQ36242646-08242AFE-70FE-4619-9432-E275E4C7FD46Q36270115-1C2CA669-2C25-451E-AE4C-D9DEE3352265Q37115414-51682E28-1BB6-4A1E-AE4C-884C5426162FQ37413127-F57D4E55-E697-4FE2-92AA-359A051B851BQ38094918-BB7EFD4A-635E-4FC0-9E62-FCD9C0F60CB5Q38180744-6D0536B7-9C1F-411E-91DE-3031538FD344Q38582589-DEE41DB0-E879-49BF-9A36-541C9459A4E3Q38977714-1766C341-C694-4294-AFE1-AABAEAB339BAQ39009379-BDC23AB7-5CF7-487F-8112-05D0B9B0E0B0Q47671139-13AC35FF-211F-4719-8637-096C6F4F477FQ53048458-3A7A3C34-6470-4E35-B6B2-279396760045Q55433291-AA640686-5A8A-4FCD-B7EE-FD056BCC4D9E
P2860
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
A phase I study of sorafenib a ...... nd non-small cell lung cancer.
@en
A phase I study of sorafenib a ...... nd non-small cell lung cancer.
@nl
type
label
A phase I study of sorafenib a ...... nd non-small cell lung cancer.
@en
A phase I study of sorafenib a ...... nd non-small cell lung cancer.
@nl
prefLabel
A phase I study of sorafenib a ...... nd non-small cell lung cancer.
@en
A phase I study of sorafenib a ...... nd non-small cell lung cancer.
@nl
P2093
P2860
P1476
A phase I study of sorafenib a ...... nd non-small cell lung cancer.
@en
P2093
C D Weekes
D R Camidge
H A Drabkin
W A Messersmith
P2860
P2888
P304
P356
10.1007/S10637-012-9812-Z
P577
2012-03-14T00:00:00Z